Delivery Order SPE2DR25D1100-SPE2DR26FDB4G
- Not listed
- The Defense Logistics Agency has awarded a delivery order valued at $10,191.22 to AmerisourceBergen Drug Corp for the supply of Mekinist 2 mg tablets (30-count units). This is a firm fixed-price, competitively awarded delivery order with no set-aside designation, scheduled for completion by January 21, 2026. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as the prime contractor and will perform the work at its corporate office location in the same municipality. This...
- The Defense Logistics Agency awarded a $21,516.67 firm fixed-price delivery order to AmerisourceBergen Drug Corp on January 21, 2026, for the supply of Mekinist 2 mg tablets (quantity: 30 units). This non-set-aside contract is scheduled for completion by February 11, 2026, with performance taking place at the contractor's corporate office in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a subsidiary of parent company Cencora, Inc., is a major pharmaceutical distributor serving federal...
- The Defense Logistics Agency awarded a Delivery Order valued at $11,195.23 to Amerisourcebergen Drug Corp (a subsidiary of Cencora, Inc.) on January 12, 2026, for the supply of Mekinist 2 mg tablets in quantities of 30. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is scheduled for completion by February 3, 2026. The awardee, based in Conshohocken, Pennsylvania, is a major pharmaceutical distributor that serves as a critical vendor for federal medical...
- The Defense Logistics Agency awarded a $9,670.51 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Mekinist 2 mg tablets (30-count units) on August 4, 2025, with an ultimate completion date of August 25, 2025. This contract represents a non-set-aside, competitively awarded delivery order executed by the prime contractor's Corporate Office, located in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen Drug Corp's larger Indefinite...
- The Defense Logistics Agency awarded a $18,566.92 delivery order to AmerisourceBergen Drug Corp on July 15, 2025, for the supply of Mekinist 2 mg tablets (30-count units). This is a firm fixed price, competitively awarded contract with no set-aside designation and an ultimate completion date of August 5, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Mekinist is a targeted cancer therapy medication, reflecting the company's...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $22,390.46 to AmerisourceBergen Drug Corp for the supply of Mekinist 2 mg tablets (30-count units) with a completion date of February 9, 2026. The contract was awarded on January 16, 2026, using firm fixed-price pricing with no set-aside designation, indicating the award was made through full and open competition. The place of performance is Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains its...
- The Defense Logistics Agency awarded a delivery order valued at $21,516.67 to AmerisourceBergen Drug Corp for the supply of Mekinist 2 mg tablets (30-count units) on January 15, 2026, with completion scheduled for February 6, 2026. This firm fixed-price contract was competitively awarded without set-aside designation and will be performed at the awardee's location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a subsidiary of parent company Cencora, Inc. (doing business as...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Mekinist 2 mg tablets in quantities of 30 units. This competitively awarded, firm fixed-price delivery order carries a ceiling value of $9,670.51 and is scheduled for completion by August 26, 2025. The contract is not subject to any small business set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $16,588.64 to AmerisourceBergen Drug Corp for supply of Mekinist 2 mg tablets (30-count units) under a firm fixed price contract. The order was competitively awarded without set-aside designation and is scheduled for completion by September 15, 2025, with performance at the contractor's facility in Conshohocken, Pennsylvania. Mekinist is a targeted cancer therapy used in melanoma and other oncological treatments, reflecting the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of Mekinist 2 mg tablets (30-count units) valued at $9,670.51 with a firm fixed price structure. This competitively awarded, non-set-aside delivery order is scheduled for completion by September 18, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. Mekinist is a targeted cancer therapy medication, reflecting the company's role in...
- SPE2DR25D1100Indefinite Delivery Contract
- SPE2DR25D1100-SPE2DR26FDB4GDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $11,195.23 to AmerisourceBergen Drug Corp for the supply of Mekinist 2 mg tablets (30-count units) on January 23, 2026, with an ultimate completion date of February 13, 2026. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp is a subsidiary of Cencora, Inc., a major pharmaceutical distributor serving federal government healthcare systems. This delivery order is executed under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract with DLA Troop Support Medical (valued at $999,999,999.00 through December 2026), which serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs. The IDC enables the company to supply a broad spectrum of pharmaceutical products, medical devices, vaccines, and specialized healthcare commodities to support the Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems worldwide. Mekinist, a targeted cancer therapy medication, represents one component of the extensive pharmaceutical portfolio delivered through this strategic contracting arrangement.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $11.2k | 1/22/26 |